|
Asthma
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
A logistic regression analysis showed that the MUC7*5-VNTR allele decreased the likelihood of a diagnosis of asthma (odds ratio, 0.173 [95% confidence interval, 0.041-0.737]; P < 0.018) and is not in a strong linkage disequilibrium with the rs9982010 (r = 0.03; odds ratio, 66; confidence interval, 5.913-736.72).
|
19820409 |
2009 |
|
Asthma
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
The MUC7*5 allele was rarer in the atopic asthmatics than in the atopic non-asthmatics (P = 0.014, OR for no asthma in atopic individuals 3.13, CI 1.01-6.10), and the difference in frequency between all asthmatics and all non-asthmatics was statistically significant (P = 0.009) while there was no difference between atopy and non-atopy (P = 0.199).
|
11378823 |
2001 |
|
Asthma
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
There was low haplotype diversity and strong association between each of the loci, and the MUC7*5 allele-carrying haplotype remained the one most strongly associated with asthma.
|
16759176 |
2006 |
|
Asthma
|
0.430 |
Biomarker
|
disease |
HPO |
|
|
|
|
Asthma
|
0.430 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Bladder Neoplasm
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
|
18026991 |
2008 |
|
Bladder Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that MUC7 is a highly specific marker for bladder cancer and may be a useful method for the molecular staging and management of bladder cancer.
|
14678183 |
2004 |
|
Bladder Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC7 is a potential marker for bladder cancer.
|
12837463 |
2003 |
|
Bladder Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
The overall sensitivity of the MUC7 test for all bladder tumor cases was 66%.
|
12478110 |
2003 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that MUC7 is a highly specific marker for bladder cancer and may be a useful method for the molecular staging and management of bladder cancer.
|
14678183 |
2004 |
|
Carcinoma of bladder
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
|
18026991 |
2008 |
|
Carcinoma of bladder
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma.
|
9865718 |
1998 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC7 is a potential marker for bladder cancer.
|
12837463 |
2003 |
|
Malignant neoplasm of urinary bladder
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
|
18026991 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results suggest that MUC7 is a highly specific marker for bladder cancer and may be a useful method for the molecular staging and management of bladder cancer.
|
14678183 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC7 is a potential marker for bladder cancer.
|
12837463 |
2003 |
|
Burning Mouth Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The genotypic polymorphisms of IL-1β -511 and +3954, and of MUC7 VNTR, had no direct associations with the development of BMS.
|
27246755 |
2017 |
|
Burning Mouth Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC7 O-glycans and measured inflammatory biomarkers were found to be similar between BMS and controls.
|
31414088 |
2019 |
|
Dental caries
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our study aimed to determine the relationship between dental caries in adults and levels of MUC5B and MUC7.
|
30745804 |
2019 |
|
Dental caries
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study does not show a correlation between the MUC7 genotypes and caries and oral hygiene of students.
|
22706105 |
2012 |
|
Caries (morphologic abnormality)
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Purpose</b>: Data currently available indicate the significance of salivary mucins MUC5B and MUC7 in the protection of teeth against caries.
|
30745804 |
2019 |
|
Caries (morphologic abnormality)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study does not show a correlation between the MUC7 genotypes and caries and oral hygiene of students.
|
22706105 |
2012 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To provide information regarding the expression of these genes in squamous metaplasia and squamous cell carcinoma, we analyzed and compared the expression of MUC1-MUC7 genes by in situ hybridization in control respiratory mucosa and lesions associated with neoplasia (hyperplasia, metaplasia and dysplasia) and squamous cell carcinomas.
|
10738241 |
2000 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To determine whether mucin (MUC) 7 gene expression can be used as a bladder tumor marker for transitional cell carcinoma in patients with bladder carcinoma.
|
12837463 |
2003 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we found MUC15 frameshift mutations (14.7% of GC and 15.2% of CRC with MSI-H), MUC 7 frameshift mutations (2.9% of GC with MSI-H) and MUC4 frameshift mutations (8.8% of GC and 3.8% of CRC with MSI-H).
|
25573589 |
2015 |